BofA analyst Travis Steed raised the firm’s price target on Becton Dickinson (BDX) to $269 from $265 and keeps a Buy rating on the shares after the company reported fiscal Q1 EPS and announced its intent to separate the Biosciences and Diagnostic Solutions business. The “spin math” suggests a sum-of-the-parts value of $269 per share for the two pieces in total, but a potential sale “could drive even more value creation,” the analyst tells investors.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Morning Movers: Roblox sinks following fourth quarter results and guidance
- Becton Dickinson to Split from Bioscience and Diagnostic Solutions Arms
- Becton Dickinson Announces Strategic Business Separation Plan
- BD sees FY25 adjusted EPS $14.30-$14.60 vs. previous view $14.25-$14.60
- Becton Dickinson to separate biosciences, diagnostic solutions business